GlassScriptPhysician profile
Yadira Dacosta
NPI 1912994294
$18,248.64
in general payments reported to CMS, 2019-2025
26 companies · $2,542 in 2025
The $2,542 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,503 · 2020: $726 · 2021: $3,248 · 2022: $1,600 · 2023: $1,151 · 2024: $1,478 · 2025: $2,542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,596 · Consulting Fee: $1,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,595.90 |
| Consulting Fee | $1,575.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $7,135.99 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Emd Serono, INC. | $2,052.02 | 2019-2025 | Mavenclad, Mavenclad |
| Abbvie INC. | $2,001.80 | 2021-2025 | Qulipta |
| Janssen Pharmaceuticals, INC | $1,316.35 | 2019-2024 | Xarelto |
| Banner Life Sciences, LLC | $1,048.99 | 2021-2023 | |
| Genentech USA, INC. | $699.45 | 2019-2024 | Ocrevus |
| Novartis Pharmaceuticals Corporation | $688.60 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $546.11 | 2019 | |
| Alexion Pharmaceuticals, INC. | $468.84 | 2019-2024 | Ultomiris, Soliris |
| Genzyme Corporation | $408.60 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $293.04 | 2020-2023 | Zeposia |
| Horizon Therapeutics Plc | $290.05 | 2022 | |
| Tg Therapeutics, INC. | $270.00 | 2025 | |
| Lundbeck LLC | $167.92 | 2024-2025 | Vyepti |
| Penumbra, INC. | $150.00 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $123.79 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $121.40 | 2021 | |
| Acadia Pharmaceuticals INC | $108.31 | 2025 | Nuplazid |
| Genentech, INC. | $104.00 | 2024 | Ocrevus |
| Allergan, INC. | $100.00 | 2019 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $47.00 | 2020-2025 | Kisunla |
| Lilly USA, LLC | $29.05 | 2023 | Emgality |
| Harmony Biosciences LLC | $25.00 | 2025 | |
| Ucb, INC. | $20.09 | 2020 | |
| Celgene Corporation | $18.86 | 2020 | |
| Pbg Puerto Rico LLC | $13.38 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yadira Dacosta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.